CSF3 and Miyoshi myopathy: In addition, the cohort of contemporaneous patients with MM enrolled prospectively and mobilized with plerixafor + G-CSF shared demographics comparable to those of patients on the GENESIS trial (Extended Data Fig. 1b and Extended Data Table 1).